BAYLOR COLLEGE OF MEDICINE

March Biosciences will present interim Phase 2 clinical data for MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy, at the American Society of Hematology Annual Meeting in December 2025.

Diakonos Oncology presented Phase 1 data showing five of seven pancreatic cancer patients treated with DOC1021 remain alive with survival times ranging from 12.9 to 45.3 months.

Oracle Health and Life Sciences and Baylor College of Medicine have announced a collaboration to advance research into alcohol-related liver disease, one of the fastest-growing causes of liver-related illness and mortality in the United States.

Pharming Group will present 12 accepted abstracts at the 2025 ACAAI Annual Scientific Meeting in Orlando, showcasing new clinical and economic data for their rare disease portfolio.

The National Institutes of Health has awarded Baylor College of Medicine $15.6 million to fund two rare disease research consortia over five years.

Greenwich LifeSciences received European regulatory approval to expand its Phase III FLAMINGO-01 clinical trial to Ireland, adding to a global network of 150 trial sites across seven countries.

Researchers at Baylor College of Medicine discovered that metformin works directly in the brain through a previously unknown pathway involving the ventromedial hypothalamus.

Greenwich LifeSciences announced that the FDA has granted Fast Track designation for GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in HLA-A*02 patients with HER2-positive breast cancer.

Baylor College of Medicine and Site Tx, Inc. have launched a multi-year collaboration to develop novel small-molecule drugs for fine-tuning immune responses across multiple diseases.

The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.